New data show early and sustained weight loss with atogepant, raising the possibility of metabolic benefits beyond migraine prevention.

On April 16, 2026, the US Court of Appeals for the Federal Circuit issued a precedential decision in Teva Pharmaceuticals International GmbH v.

A statistically significant reduction in the mean number of monthly headache days (vs baseline) was observed for the CGRP-targeted therapies and propranolol ...

Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...